Hyperfine, Inc. reported that a large, prospective, multi‑center observational study published in the November 2025 issue of Stroke: Vascular and Interventional Neurology confirms the next‑generation Swoop® portable MRI system’s ability to detect very small ischemic strokes quickly and reliably. The study, which included 95 patients from Massachusetts General Hospital, Buffalo General Medical Center, and Yale New Haven Hospital, compared the new Swoop scanner with its predecessor and evaluated two diffusion‑weighted imaging (DWI) sequences.
The multi‑directional DWI sequence on the next‑generation scanner achieved 100 % sensitivity and 100 % specificity for lesions larger than 1.0 mL and identified strokes as small as 2.8 mm (0.15 mL). Scan times were reduced by roughly 30 %, allowing the system to deliver high‑quality, rapid brain imaging at the bedside. These metrics demonstrate that the Swoop system can serve as an AI‑powered “tissue clock,” a critical capability for emergency department stroke triage.
The study’s findings reinforce Hyperfine’s strategy to expand the Swoop system beyond hospital critical‑care units into emergency departments and outpatient neurology offices. By proving that the device can detect small strokes in a clinically feasible timeframe, the company gains a stronger evidence base to support broader commercialization, potentially enlarging the addressable market and accelerating adoption in acute care settings.
"Stroke detection represents a critical driver of the Swoop® system’s expansion into emergency departments," said Maria Sainz, President and CEO of Hyperfine. Dr. Taylor Kimberly, Chief of the Neurocritical Care Division at Mass General Brigham, added, "With this study, we took the next step and evaluated the capability of ultra‑low‑field MRI with advanced, multi‑directional DWI sequences to detect very small ischemic lesions, confirming the system’s clinical value."
Hyperfine’s Swoop system is FDA‑cleared for brain imaging in patients of all ages and has built on prior research such as the ACTION PMR study. The company is also pursuing global expansion, with distribution agreements in Europe and the Middle East, and is evaluating the system’s utility in outpatient neurology offices through studies like NEURO PMR. The November 2025 study therefore represents a pivotal milestone that validates the next‑generation hardware and Optive AI software, supporting Hyperfine’s broader commercialization plan and positioning the company for accelerated market penetration.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.